drug · antibody
talquetamab
Marketedupdated 3mo agoby $JNJ JOHNSON & JOHNSON🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and neoplasm.
targets
G-protein coupled receptor family C group 5 member DT cell surface glycoprotein CD3
all catalysts(8)
approval · 8
Aug 9, 2023
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Nov 16, 2023
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Feb 20, 2024
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Jul 2, 2024
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Dec 2, 2024
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Aug 19, 2025
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Oct 2, 2025
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Mar 5, 2026
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Trials studying talquetamab
- phase3A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- phase1A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- phase2A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- phase2Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
- phase1A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
- phase2Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- phase2Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
- phase2A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
News(4)
- Legend Biotech CEO abruptly steps down without permanent replacementIn a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.fiercebiotech · 19d ago
- Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaNovo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.biopharma_dive · 22d ago
- J&J multiple myeloma drug gains edge in earlier stage diseaseThe latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.biopharma_dive · 2mo ago
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 3mo ago
Data sources
last refreshed 11m ago
Found something off?
comments(0)
5-min edit window · permanent after that